An Update on Inhibitors of Human 14 kDa Type II s PLA2 in Development

Recent progress in the development of inhibitors of human Type II s PLA2 as potential anti inflammatory agents is presented. While many companies have curtailed their efforts in the PLA2 area, Eli Lilly and Shionogi are continuing to advance LY 315920 (S 5920) as a potential treatment for sepsis and other diseases that have an inflammatory component. The Lilly developmental effort leading to LY 315920 is extensively reviewed, as well as the current status of other small molecular weight inhibitors of Type II s PLA2 that have been reported to be in late stage development.